Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral hepatitis B.

Ching Lung Lai1, Vlad Ratziu, Man-Fung Yuen

  • 1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, People's Republic of China. hrmelcl@hkucc.hku.hk

Lancet (London, England)
|December 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations between gut microbiome and 24-hour blood pressure variability: a cross-sectional study highlighting sex differences and potential therapeutic targets.

Gut microbiome (Cambridge, England)·2026
Same author

Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis.

The American journal of gastroenterology·2026
Same author

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

The New England journal of medicine·2026
Same author

The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.

The lancet. Gastroenterology & hepatology·2026
Same author

GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.

Hepatology (Baltimore, Md.)·2026
Same author

Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort.

Journal of hepatology·2026

Hepatitis B virus infection affects over 400 million people globally, leading to liver cancer and other severe conditions. Advances in vaccines and treatments offer hope for managing chronic hepatitis B (HBV) infection.

Area of Science:

  • Hepatology
  • Virology
  • Oncology

Background:

  • Chronic hepatitis B virus (HBV) infection impacts over 400 million individuals worldwide.
  • HBV is a leading cause of liver cancer, gastrointestinal hemorrhage, and ascites.
  • Significant progress in HBV diagnosis and treatment has been achieved.

Purpose of the Study:

  • To review recent breakthroughs in hepatitis B diagnosis and treatment.
  • To discuss the role of molecular virology in understanding HBV mutants.
  • To explore the clinical significance of low viral load and genotypes in HBV infection.

Main Methods:

  • Review of current literature on hepatitis B diagnosis and treatment.
  • Analysis of advances in molecular virology, including HBV mutants.

Related Experiment Videos

  • Investigation into the clinical significance of viral load and genotypes.

    • Main Results:

    • Hepatitis B vaccine effectively reduces liver cancer incidence.
    • Molecular virology has advanced understanding of naturally occurring and treatment-induced HBV mutants.
    • Current monotherapies (interferon, lamivudine, adefovir dipivoxil) rarely eradicate HBV but reduce viral replication, necroinflammation, and fibrosis progression.
    • Nucleoside analogues like lamivudine show potential in reversing liver cirrhosis.

    Conclusions:

    • Hepatitis B vaccination is crucial for preventing liver cancer.
    • Ongoing research in molecular virology is key to understanding and combating HBV.
    • While not curative, current therapies significantly improve outcomes for chronic HBV patients, with potential for liver damage reversal.